NORPACT-1
Regimen
- Experimental
- Neoadjuvant FOLFIRINOX x 4 cycles, then surgery, then 8 cycles adjuvant FOLFIRINOX.
- Control
- Upfront surgery, then 12 cycles adjuvant FOLFIRINOX.
Population
Strictly resectable pancreatic head cancer, ECOG 0-1, Danish/Finnish/Norwegian/Swedish 12-center trial.
Key finding
NORPACT-1 is the first phase 2 RCT to show neoadjuvant FOLFIRINOX in strictly resectable (not borderline) PDAC fails to improve 18-month OS and numerically harms it vs upfront surgery. Implementation of neoadjuvant FFX proved challenging (~20% could not receive surgery).
Source: PMID 38237621